XTalks

DECEMBER 28, 2023

BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. The trial is set to occur across the US, the European Union (EU) and selected global locations.

Trials 97

Trials Clinical Trials Clinical Trials Antibody 97

Pharmaceutical Technology

APRIL 14, 2023

TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients. The first-in-class, clinical-stage antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN 6), TORL-1-23 is being developed to treat patients across several cancer types. CLDN 18.2).

Development 264

Development Clinical Trials Clinical Trials Life Science 264

XTalks

MAY 2, 2022

This year, the monoclonal antibody lecanemab is approaching final stages of investigation as a treatment for targeting the A? The Phase IIb clinical trial focused on the long-term clinical outcomes and safety for patients with MCI and amyloid pathology (early AD). The main pathological markers of AD are beta-amyloid (A?)

Clinical Trials 98

Clinical Trials Clinical Trials Antibody Trials 98

BioTech 365

JANUARY 4, 2021

Tiziana Life Sciences plc (“Tiziana” or the “Company”) – Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil Tiziana Life Sciences plc (“Tiziana” … Continue reading (..)

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

Drug Discovery World

APRIL 27, 2023

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. We believed that having a fully human CD3 antibody may offer benefits to patients across many different chronic disease indications.”

Antibody 52

Antibody Development Life Science FDA Approval 52

XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. COVID-19: The Pandemic and the Vaccines.

Life Science 98

Life Science Vaccination Vaccine Trials 98

XTalks

AUGUST 10, 2022

Ayesha also talked about the FDA approval of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab-deruxtecan) for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science FDA Approval Drugs Licensing 52

The Pharma Data

MARCH 15, 2022

Global Head of Research and Development for Sanofi “ The collaboration with Blackstone will accelerate our ability to offer patients a subcutaneous anti-CD38 antibody therapy that we believe will be innovative and more convenient. Sarclisa ® is a monoclonal antibody that targets a specific epitope on the CD38 receptor on MM cells.

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

XTalks

JANUARY 17, 2024

Given this hotbed of activity, innovation in the space to drive faster decisions and more efficient trials is intense. They discussed the top new trends in oncology trial design that sponsors are either incorporating into clinical trials or need to start planning to include.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Gene Therapy 124

The Pharma Data

JANUARY 3, 2021

This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. The last patients in the trial received their final dose on 21 December 2020. The topline data from the trial is expected to be available in January 2021. About Tiziana Life Sciences.

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

XTalks

NOVEMBER 3, 2021

The authorization was based on trial data that showed the vaccine was safe, well-tolerated and induced robust immune responses among children in this age group; side effects were generally mild to moderate. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Drug Delivery Systems Vaccination Vaccine 52

The Pharma Data

NOVEMBER 30, 2020

Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences. About Tiziana Life Sciences. NEW YORK and LONDON, Dec.

Life Science 40

Life Science Antibody Clinical Trials Clinical Trials 40

Pharmaceutical Technology

JUNE 9, 2023

Co-led by Venrock Healthcare Capital Partners (Venrock) and Enavate Sciences, the financing round has seen participation from new investors Wellington Management and Bain Capital Life Sciences. It is also preparing for a swift transition to Phase III development.

Clinical Development 147

Clinical Development Development Life Science Clinical Trials 147

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19.

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

XTalks

JULY 25, 2022

The BLA, which grants permission to distribute a biological therapy across states in the US, was accepted based on data from the company’s Phase III trial. Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). Byondis’ Clinical Trial Pipeline.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

XTalks

MAY 29, 2024

Recognized on May 30 each year, World MS Day brings together global communities, healthcare professionals and life sciences industries to share stories, raise awareness and support those affected by multiple sclerosis (MS). These seek to protect the nervous system from MS damage and slow disease progression.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Life Science 52

The Pharma Data

NOVEMBER 10, 2020

First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease.

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

pharmaphorum

MARCH 15, 2022

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development. The post Blackstone funds new trials of Sanofi’s Sarclisa in myeloma appeared first on.

Trials 97

Trials Sales Drug Delivery Antibody 97

BioSpace

OCTOBER 14, 2021

Read about TFF Pharmaceuticals and Augmenta Bioworks' dry powder COVID-19 antibody formula, the world's first gene editing clinical trial for PKU, Bayer's COVID-19 vaccine and other key developments in life sciences research.

Gene Editing 72

Gene Editing Life Science Clinical Trials Clinical Trials 72

pharmaphorum

MAY 20, 2021

Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.

Antibody 52

Antibody Development Clinical Development Life Science 52

XTalks

MAY 4, 2023

A blood test can detect antibodies to gluten, but a definitive diagnosis requires a biopsy of the small intestine. However, there are ongoing clinical trials for celiac disease to investigate potential new treatments. How does Beyond Celiac spread awareness about research and clinical trials for celiac disease?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

XTalks

MARCH 20, 2024

When it comes to leadership in clinical trials today, what qualities are necessary to navigate the evolving landscape of clinical research effectively? Continue reading to explore effective leadership in clinical trials. Christine Enciso: My journey in clinical research spans over 28 years, mainly focused on clinical trial operations.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

XTalks

JUNE 23, 2021

The team also talked about Regeneron’s monoclonal antibody treatment for COVID-19 that has been shown to reduce the risk of deaths by 20 percent among hospitalized COVID-19 patients in recent results from the UK RECOVERY trial. The treatment consists of two monoclonal antibodies that target the spike protein of SARS-CoV-2.

Antibody 52

Antibody Life Science Protein Vaccination 52

XTalks

OCTOBER 27, 2022

Patients are eligible for the drug if they have previously received four or more lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody — this can include a combination of the different drugs.

FDA Approval 52

FDA Approval Antibody Drugs Trials 52

Drug Discovery World

MARCH 31, 2023

As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.

Drugs 52

Drugs Antibody Vaccination Vaccine 52

Drug Discovery World

OCTOBER 11, 2023

MinervaX is currently progressing two Phase II clinical trials in 470 pregnant persons across Denmark, United Kingdom, Uganda and South Africa.

Vaccination 59

Vaccination Vaccine Clinical Trials Clinical Trials 59

XTalks

DECEMBER 10, 2021

Biohaven Pharmaceuticals revealed positive top line results from a late-stage trial which show that its migraine medication Zavegepant provides “ultra-rapid” pain relief in just 15 minutes. Zavegepant is an antibody drug that prevents binding of the calcitonin gene-related peptide (CGRP) to the CGRP receptor.

FDA Approval 98

FDA Approval Trials Drugs Sales 98

Pharma in Brief

DECEMBER 17, 2023

On December 4, 2023, the Federal Court held that a patent claiming a formulation of adalimumab, a monoclonal antibody used to treat autoimmune diseases, is valid and is being infringed by a biosimilar product. Even though the risk is low to those patients, it is preferable to compensate AbbVie rather than take SIMLANDI off the market.

Antibody 52

Antibody Production Regulation Marketing 52

XTalks

MAY 7, 2021

Novavax published the latest results from a Phase IIb clinical trial conducted in South Africa evaluating the safety and efficacy of NVX-CoV2373, appearing in the NEJM ’s May 6, 2021 issue. Earlier results from a more complete analysis of trial data shared in March confirmed a high level efficacy of 86.3 1.351 variant. 1.351 variant.

Protein 97

Protein Vaccination Vaccine Trials 97

Drug Discovery World

FEBRUARY 28, 2024

Using IgE to treat cancer In the UK, a Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

Development 64

Development Research Drugs Antibody 64

XTalks

FEBRUARY 29, 2024

In a statement , the company said it will discontinue Aduhelm to focus efforts on its other amyloid beta-directed antibody Leqembi (lecanemab) for Alzheimer’s and focus on developing other new treatments. Two years after its approval in 2021 , Biogen has decided to pull the plug on its Alzheimer’s drug Aduhelm (aducanumab).

Drugs 59

Drugs FDA Approval Antibody Life Science 59

XTalks

AUGUST 8, 2022

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

XTalks

APRIL 17, 2023

Monoclonal antibodies are gaining attention as alternative or additive treatments for atopic dermatitis. Lebrikizumab is a new and investigational monoclonal antibody designed to selectively inhibit IL-13. “In The safety of this trial was consistent with previously reported atopic dermatitis trials.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

Advarra

MARCH 21, 2023

While drugs require Phase I-III clinical trials—and are also subject to post-approval tracking—digital therapeutics, devices, and IVDs may be able to leverage bench testing, animal studies, pilot studies, and training sets. The greater the risk, the more likely a series of trials for market clearance or approval will be required.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Production 52

XTalks

AUGUST 14, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its bispecific antibody Talvey (talquetamab-tgvs) received US Food and Drug Administration (FDA) approval as a fifth-line treatment for adult patients with heavily pretreated multiple myeloma. Results were similar at the higher 0.8 mg/kg dose with an ORR of 73.6

FDA Approval 97

FDA Approval Antibody Immune Response Drugs 97

The Pharma Data

NOVEMBER 1, 2020

Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Tiziana Life Sciences plc. (“Tiziana” or the “Company”). . (“Tiziana” or the “Company”). About Tiziana Life Sciences.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Life Science 52

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. We aim to continue to ‘open up’ the druggable antibody space.”

Drugs 52

Drugs Antibody DNA Gene Therapy 52